Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Memphis, United States. In N Engl J Med, 2014
Kinase-activating alterations were identified in 91% of patients with Ph-like ALL; rearrangements involving ABL1, ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, PTK2B, TSLP, or TYK2 and sequence mutations involving FLT3, IL7R, or SH2B3 were most common.
The BCR-ABL story: bench to bedside and back.
Los Angeles, United States. In Annu Rev Immunol, 2003
Imatinib mesylate (Gleevec, STI571, or CP57148B) is a direct inhibitor of ABL (ABL1), ARG (ABL2), KIT, and PDGFR tyrosine kinases.